Vitamin K-dependent carboxylation of matrix Gla-protein: A crucial switch to control ectopic mineralization

Trends in Molecular Medicine

Volumn 19, Issue 4, 2013, Pages 217-226

  Schurgers, Leon J ^a   Uitto, Jouni ^b   Reutelingsperger, Chris P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apoptosis; Arteriovenous malformations; Biomarker; Cardiovascular disease; Ectopic mineralization; Matrix Gla protein; Vascular calcification; Vitamin K; Vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; BIOLOGICAL MARKER; MATRIX GLA PROTEIN; OSTEOCALCIN; SERINE; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

APOPTOSIS; BONE MINERALIZATION; CARBOXYLATION; DRUG MECHANISM; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; VITAMIN K METABOLISM;

BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEINS; CARDIOVASCULAR DISEASES; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MUSCLE, SMOOTH, VASCULAR; RISK FACTORS; VASCULAR CALCIFICATION; VITAMIN K;

EID: 84875843626     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.12.008     Document Type: Review

References (82)

1. Luo G., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997, 385:78-81.
2. Murshed M., et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J. Cell Biol. 2004, 165:625-630.
3. Price P., et al. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1400-1407.
4. Schurgers L.J., et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007, 109:2823-2831.
5. Schurgers L.J., et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1629-1633.
6. Roijers R.B., et al. Microcalcifications in early intimal lesions of atherosclerotic human coronary arteries. Am. J. Pathol. 2011, 178:2879-2887.
7. Shroff R.C., et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008, 118:1748-1757.
8. Chatrou M.L.L., et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012, 26:155-166.
9. Price P., et al. Conserved phosphorylation of serines in the Ser-X-Glu/Ser(P) sequences of the vitamin K-dependent matrix Gla protein from shark, lamb, rat, cow, and human. Protein Sci. 1994, 3:822-830.
10. Wajih N., et al. Processing and transport of matrix gamma-carboxyglutamic acid protein and bone morphogenetic protein-2 in cultured human vascular smooth muscle cells: evidence for an uptake mechanism for serum fetuin. J. Biol. Chem. 2004, 279:43052-43060.
11. Alexander M.R., Owens G.K. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu. Rev. Physiol. 2012, 74:13-40.
12. Fleckenstein-Grun G., et al. Calcium overload - an important cellular mechanism in hypertension and arteriosclerosis. Drugs 1992, 44:23-30.
13. Reynolds J.L., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J. Am. Soc. Nephrol. 2004, 15:2857-2867.
14. Kapustin A.N., et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ. Res. 2011, 109:e1-e12.
15. Proudfoot D., et al. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ. Res. 2000, 87:1055-1062.
16. Jia G., et al. Role of matrix Gla protein in angiotensin II-induced exacerbation of vascular calcification. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H523-H532.
17. Pi W., et al. BMP-2 up-regulates PTEN expression and induces apoptosis of pulmonary artery smooth muscle cells under hypoxia. PLoS ONE 2012, 7:e35283.
18. O'Young J., et al. Matrix gla protein inhibits ectopic calcification by a direct interaction with hydroxyapatite crystals. J. Am. Chem. Soc. 2011, 133:18406-18412.
19. Price P.A., et al. Mineralization by inhibitor exclusion: the calcification of collagen with fetuin. J. Biol. Chem. 2009, 284:17092-17101.
20. Steitz S.A., et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ. Res. 2001, 89:1147-1154.
21. Speer M.Y., et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ. Res. 2009, 104:733-741.
22. Sun Y., et al. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ. Res. 2012, 111:543-552.
23. Boström K.I., et al. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ. Res. 2011, 109:564-577.
24. Nakagawa Y., et al. Paracrine osteogenic signals via bone morphogenetic protein-2 accelerate the atherosclerotic intimal calcification in vivo. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1908-1915.
25. Yao Y., et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ. Res. 2010, 107:485-494.
26. Zebboudj A.F., et al. Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J. Cell. Biochem. 2003, 90:756-765.
27. Winnier G., et al. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 1995, 9:2105-2116.
28. Yao Y., et al. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1. J. Biol. Chem. 2006, 281:33921-33930.
29. Chang K., et al. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis. Circulation 2007, 116:1258-1266.
30. Csiszar A., et al. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation 2005, 111:2364-2372.
31. Yao Y., et al. Matrix Gla protein deficiency causes arteriovenous malformations in mice. J. Clin. Invest. 2011, 121:2993-3004.
32. Pai A., et al. Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am. J. Pathol. 2011, 178:764-773.
33. Bunton T.E., et al. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ. Res. 2001, 88:37-43.
34. Price P.A., et al. The elastic lamellae of devitalized arteries calcify when incubated in serum: evidence for a serum calcification factor. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1079-1085.
35. Bouvet C., et al. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:856-862.
36. Schurgers L.J., et al. Vitamin k-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS ONE 2012, 7:e43229.
37. Pfendner E.G., et al. Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum. J. Med. Genet. 2007, 44:621-628.
38. Gheduzzi D., et al. Matrix Gla protein is involved in elastic fiber calcification in the dermis of pseudoxanthoma elasticum patients. Lab. Invest. 2007, 87:998-1008.
39. -/-). Biochem. Biophys. Res. Commun. 2007, 364:208-213.
40. Vanakker O.M., et al. Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J. Invest. Dermatol. 2007, 127:581-587.
41. Vanakker O.M., et al. Low serum vitamin K in PXE results in defective carboxylation of mineralization inhibitors similar to the GGCX mutations in the PXE-like syndrome. Lab. Invest. 2010, 90:895-905.
42. Váradi A., et al. ABCC6 as a target in pseudoxanthoma elasticum. Curr. Drug Targets 2011, 12:671-682.
43. -/- mice, a model for pseudoxanthoma elasticum. Cell Cycle 2011, 10:701-707.
44. Gorgels T.G.M.F., et al. Vitamin K supplementation increases vitamin K tissue levels but fails to counteract ectopic calcification in a mouse model for pseudoxanthoma elasticum. J. Mol. Med. 2011, 89:1125-1135.
45. Brampton C., et al. Vitamin K does not prevent soft tissue mineralization in a mouse model of pseudoxanthoma elasticum. Cell Cycle 2011, 10:1810-1820.
46. Schurgers L.J., et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J. Thromb. Haemost. 2007, 5:2503-2511.
47. Sweatt A., et al. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J. Thromb. Haemost. 2003, 1:178-185.
48. Holden R., et al. Vitamins K and D status in stages 3-5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010, 5:590-597.
49. Westenfeld R., et al. Effect of vitamin K(2) supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am. J. Kidney Dis. 2012, 59:186-195.
50. Schlieper G., et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J. Am. Soc. Nephrol. 2011, 22:387-395.
51. Alexopoulos N., Raggi P. Calcification in atherosclerosis. Nat. Rev. Cardiol. 2009, 6:681-688.
52. Aikawa E., et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007, 116:2841-2850.
53. Vengrenyuk Y., et al. A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:14678-14683.
54. Munroe P., et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat. Genet. 1999, 21:142-144.
55. Hall J.G., et al. Maternal and fetal sequelae of anticoagulation during pregnancy. Am. J. Med. 1980, 68:122-140.
56. Menger H., et al. Vitamin K deficiency embryopathy: a phenocopy of the warfarin embryopathy due to a disorder of embryonic vitamin K metabolism. Am. J. Med. Genet. 1997, 72:129-134.
57. O'Donnell C.J., et al. Matrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcification. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2769-2774.
58. Schurgers L.J., et al. Characteristics and performance of an immunosorbent assay for human matrix Gla-protein. Clin. Chim. Acta 2005, 351:131-138.
59. Hendig D., et al. The local calcification inhibitor matrix Gla protein in pseudoxanthoma elasticum. Clin. Biochem. 2008, 41:407-412.
60. Cranenburg E.C.M., et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J. Vasc. Res. 2008, 45:427-436.
61. Parker B.D., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann. Intern. Med. 2010, 152:640-648.
62. Li Q., et al. Co-existent pseudoxanthoma elasticum and vitamin K-dependent coagulation factor deficiency: compound heterozygosity for mutations in the GGCX gene. Am. J. Pathol. 2009, 174:534-540.
63. Cranenburg E.C.M., et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb. Haemost. 2010, 104:811-822.
64. Ueland T., et al. Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J. Intern. Med. 2010, 268:483-492.
65. Ueland T., et al. Circulating levels of non-phosphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chronic heart failure. Clin. Sci. 2011, 121:119-127.
66. Schurgers L.J., et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin. J. Am. Soc. Nephrol. 2010, 5:568-575.
67. Price P., et al. Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. J. Biol. Chem. 2002, 277:3926-3934.
68. Ferron M., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142:296-308.
69. Knapen M.H.J., et al. Association of vitamin K status with adiponectin and body composition in healthy subjects: uncarboxylated osteocalcin is not associated with fat mass and body weight. Br. J. Nutr. 2012, 108:1017-1024.
70. Shanahan C.M., et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ. Res. 2011, 109:697-711.
71. Ewence A.E., et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ. Res. 2008, 103:e28-e34.
72. Yao Y., et al. Matrix GLA protein, an inhibitory morphogen in pulmonary vascular development. J. Biochem. 2007, 282:30131-30142.
73. Tang Z., et al. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat. Commun. 2012, 3:875.
74. Shroff R.C., et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J. Am. Soc. Nephrol. 2010, 21:103-112.
75. Liberman M., et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler. Thromb. Vasc. Biol. 2008, 28:463-470.
76. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2008, 3:1599-1605.
77. Atkinson J. Age-related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences. J. Appl. Physiol. 2008, 105:1643-1651.
78. Ketteler M., et al. Pathogenesis of vascular calcification in dialysis patients. Clin. Exp. Nephrol. 2005, 9:265-270.
79. Drüeke T.B., Massy Z.A. Atherosclerosis in CKD: differences from the general population. Nat. Rev. Nephrol. 2010, 6:723-735.
80. Huang H., et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 2001, 103:1051-1056.
81. Uitto J., et al. Pseudoxanthoma elasticum: molecular genetics and putative pathomechanisms. J. Invest. Dermatol. 2010, 130:661-670.
82. Uitto J., Jiang Q. Pseudoxanthoma elasticum-like phenotypes: more diseases than one. J. Invest. Dermatol. 2007, 127:507-510.